- Though there’s little awareness, liver diseases are some of the most common diseases affecting 150 million people in the U.S., driven by non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, alcohol use and viral hepatitis.
- Liver diseases are one of the biggest, underserved problems in healthcare. They lead to terrible, irreversible outcomes for most patients and are driving a huge portion of societal health spending.
- Mortality rates due to chronic liver disease and cirrhosis are on an alarming upward trajectory, with more than two million deaths globally each year.
Impacting Millions and on the Rise
Urgent Need for Therapeutic Progress
Despite these staggering statistics and significant advances in treating some liver diseases such as hepatitis C, little progress has been made to address the life-threatening complications of severe liver disease.
New interventions to manage the morbidity and mortality of severe liver disease are needed urgently.
In people with severe liver disease, the liver’s natural ability to regenerate itself is compromised to the point where the body can no longer create and maintain a sufficient number of hepatocytes needed to conduct vital biosynthetic, metabolic and detoxifying functions. This results in life-threatening disease complications and high morbidity.
While liver transplantation is a viable and curative option, many patients are ineligible. For those who are eligible, the number of patients who could potentially benefit from transplant are far outstripped by the available supply of donor organs.
Translating Biological Insights to Deliver Breakthrough Therapeutics
Deeply understanding and interrogating the biological processes that lead to recurring liver injury, which in turn inhibits the liver’s innate ability to regenerate itself and maintain hepatocyte homeostasis, is a major focus of our work at Ambys.
We are rapidly translating these insights about liver injury to advance breakthrough therapies that can spur liver regeneration and restore function.